Organisms
|
Number
of cases |
Percentage
|
Staphylococci aureus |
50 |
39.4 |
Pseudomonas
aeroginosa |
18 |
14.2 |
Klebsiella pneumoniae |
17 |
13.4 |
Escherichia coli |
11 |
8.7 |
Acinetobacter |
10 |
7.9 |
Coagulase negative
Staphylococci |
5 |
3.9 |
Proteus mirabilis |
5 |
3.9 |
Klebsiellaoxytoca |
3 |
2.4 |
Proteus vulgaris |
3 |
2.4 |
Providencia stuartii |
3 |
2.4 |
Enterococci |
2 |
1.6 |
Total
(50) |
Methicillin
resistant R |
SA (31) S (62%) |
Methicillin
sensitive |
SA
(19%) S (38%) |
Penicillin |
32 (100%) |
0 |
19 (100%) |
0 |
Amoxicillin |
30 (97%) |
1 (3.22%) |
16 (84.2%) |
3 (15.79%) |
Erythromycin |
28(91.42%) |
3 (9.67%) |
7 (36.84%) |
12(63.16%) |
Roxithromycin |
27 (87.1%) |
4 (12.9%) |
5 (26.31%) |
14(73.68%) |
Ciprofloxacin |
29(93.54%) |
2 (6.45%) |
7 (36.84%) |
12(63.16%) |
Ofloxacin |
23(74.19%) |
8 (25.81%) |
6 (31.58%) |
13(68.42%) |
Gentamycin |
31 (100%) |
0 |
14(73.68%) |
5 (26.31%) |
Amikacin |
18(58.06%) |
13(41.93%) |
1 (5.26%) |
18(94.74%) |
Chloramphenicol |
0 |
31 (100%) |
0 |
19 (100%) |
Cefotaxime |
16 (51.6%) |
15(48.39%) |
2 (10.52%) |
17(89.47%) |
Linezolid |
0 |
31 (100%) |
0 |
19 (100%) |
Vancomycin |
0 |
31 (100%) |
0 |
19 (100%) |
|
Acinetobacter |
Proteus
mirabilis |
Proteus
vulgaris |
Providencia Stuartii |
|||||
Total
|
10 |
% |
5 |
% |
3 |
% |
3 |
% |
|
Gentamycin |
S |
3 |
30 |
- |
- |
- |
- |
1 |
33.3 |
R |
7 |
70 |
5 |
100 |
3 |
100 |
2 |
66.7 |
|
Ciprofloxacin |
S |
1 |
10 |
3 |
60 |
2 |
66.7 |
- |
- |
R |
9 |
90 |
2 |
40 |
1 |
33.3 |
3 |
100 |
|
Cotrimoxale |
S |
- |
- |
4 |
80 |
1 |
33.3 |
3 |
100 |
R |
- |
- |
1 |
20 |
2 |
66.7 |
- |
- |
|
Ampicillin |
S |
- |
- |
3 |
60 |
- |
- |
- |
- |
R |
- |
- |
2 |
40 |
3 |
100 |
3 |
100 |
|
Chloramphenicol |
S |
2 |
20 |
2 |
40 |
1 |
33.3 |
2 |
66.7 |
R |
8 |
80 |
3 |
60 |
2 |
66.7 |
1 |
33.3 |
|
Amikacin |
S |
10 |
10 |
4 |
80 |
3 |
100 |
3 |
100 |
R |
- |
90 |
1 |
20 |
- |
- |
- |
- |
|
Cefotaxime |
S |
2 |
20 |
3 |
60 |
2 |
66.7 |
1 |
33.3 |
R |
8 |
80 |
2 |
40 |
1 |
33.3 |
2 |
66.7 |
|
Polymixin B |
S |
8 |
80 |
- |
- |
- |
- |
- |
- |
R |
2 |
20 |
- |
- |
- |
- |
- |
- |
|
Carbenicillin |
S |
9 |
90 |
- |
- |
- |
- |
- |
- |
R |
1 |
10 |
- |
- |
- |
- |
- |
- |
|
Tetracycline |
S |
- |
- |
4 |
80 |
3 |
100 |
2 |
66.7 |
R |
- |
- |
1 |
20 |
- |
- |
1 |
33.3 |
|
Cefuroxime |
S |
5 |
50 |
1 |
20 |
- |
- |
- |
- |
R |
5 |
50 |
4 |
80 |
3 |
100 |
3 |
100 |
|
Amoxicillin |
S |
4 |
40 |
4 |
80 |
2 |
66.7 |
3 |
100 |
R |
6 |
60 |
1 |
20 |
1 |
33.3 |
- |
- |
|
Ofloxacin |
S |
2 |
20 |
4 |
80 |
3 |
100 |
- |
- |
R |
8 |
80 |
1 |
20 |
- |
- |
3 |
100 |
|
Netilymicin |
S |
2 |
20 |
1 |
20 |
- |
- |
- |
- |
R |
8 |
80 |
4 |
80 |
3 |
100 |
3 |
100 |
|
Ceftriaxone |
S |
3 |
30 |
3 |
60 |
2 |
66.7 |
1 |
33.3 |
R |
7 |
70 |
2 |
40 |
1 |
33.3 |
2 |
66.7 |
|
Ceftizidime |
S |
6 |
60 |
4 |
80 |
3 |
100 |
1 |
33.3 |
R |
4 |
40 |
1 |
20 |
- |
- |
2 |
66.7 |
|
Cephalexin |
S |
4 |
40 |
1 |
20 |
- |
- |
1 |
33.3 |
R |
6 |
60 |
4 |
80 |
3 |
100 |
2 |
66.7 |
Author
and place |
Year
|
Total
studied |
%
MRSA |
Lesseva et al, [13] Scientific Institute of
Emergency Medicine, Sofia, Bulgaria |
1994 |
4552 |
23.8 |
R.L. Bang et al, [14] Department of Microbiology,
Ibn Sina Hospital, Kuwait |
1996 |
79 |
41 |
Sanyal et al, [15] Ibn Sina Hospital, Kuwait |
1996 |
943 |
92 |
W. Song et al, [10] Department of Clinical
Pathology, South Korea |
1996 |
2190 |
98 |
Present study, Davangere, Karnataka |
2014 |
100 |
62 |